Du traitement du cancer à la maladie cœliaque : Teva vise des revenus de 7 milliards de dollars
Le géant pharmaceutique israélien a présenté un plan visant à augmenter les revenus des médicaments de marque, à améliorer les marges de rentabilité et à lancer un médicament innovant chaque année. Dans le pipeline de…
Évaluation
Teva is laying out a growth plan that bets heavily on its pipeline of original drugs, not just generics. With seven advanced programs carrying a combined peak sales potential above $10 billion, the company is signaling it can return to serious revenue expansion. The target of $7 billion in sales and a new innovative drug launch each year sets a high bar. Watch whether the pipeline delivers on those peak projections, because that will determine if Teva can sustain the profitability improvements it also promised.